System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Pascal Joly is an expert in Dermatology at Centre Hospitalier Universitaire de Rouen (France). As of October 2026, ScienceLeadR ranks Pascal Joly in the top 1% of experts worldwide for Sexually Transmitted Diseases, Autoimmune Diseases and Skin Diseases, Vesiculobullous. Pascal Joly has authored 687 publications, the most recent in 2026, and is an investigator in 35 clinical trials, 7 of them ongoing. SLR score: 2,468 (community average: 125). How the SLR is computed.

LeadR Profile

Pascal Joly Centre Hospitalier Universitaire de Rouen France
2 468 ScienceLeadR Reputation 2468

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Immunology - Public Health - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1994 - 2026
Source: PubMed

ERN-Skin

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 687

Citations

Citations: 31 048 1st author: 57 Last author: 152 Unique author: 16

Main journals

Ann Dermatol Venereol 197
J Eur Acad Dermatol Venereol 72
Br J Dermatol 50
J Am Acad Dermatol 33
Annales de dermatologie et de vénéréologie, FMC 30

Best Journals

N Engl J Med 8
Nat Rev Dis Primers 2
Nature 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Correction: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
PMID 42789172 — safety, alopecia areata, therapeutics, alopecia		Am J Clin Dermatol20260
Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.
PMID 42723554 — syphilis, safety, prednisone, adrenal cortex hormones, desmogleins, therapeutics, pemphigus, dermatology		Br J Dermatol20260
Expert consensus on oral management in autoimmune bullous diseases, erythema multiforme and SJS/TEN.
PMID 42482572 — oral manifestations, sexually transmitted diseases, hygiene, mouth mucosa, oral hygiene, skin diseases, epidermolysis bullosa, autoimmune diseases, erythema multiforme, therapeutics, mucous membrane, pemphigus, erythema		J Eur Acad Dermatol Venereol20260
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.
PMID 42390708 — safety, rituximab, therapeutics, pemphigus		Dermatol Ther (Heidelb)20260
Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.
PMID 42363627 — mortality, syphilis, incidence, pemphigoid, bullous, mucous membrane, dermatology, membranes		Br J Dermatol20260

Clinical Studies 35

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 17 Study Director: 1

By phase:

Phase 3 16
N/A 11
Phase 4 4
Phase 2/Phase 3 2
Phase 1 1
Phase 2 1

By status:

Completed 20
Recruiting 8
Unknown 4
Active not recruiting 1
Not yet recruiting 1
Terminated 1

By type:

Interventional 27
Observational 8

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 3
multicentric5to9 3
multicentricup10 18

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

7 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Randomized clinical trial to compare oral isotretinoin to standard of care in moderate acne skin of color patients
2023-507519-36-00 — isotretinoin, skin		Phase 3Recruiting2025
Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
NCT06447480 — isotretinoin, skin, quality of life, doxycycline, adapalene, lymecycline, hyperpigmentation, acne vulgaris, therapeutics, pigmentation, tretinoin		Phase 3Recruiting2025
Screening for Adrenal Insufficiency During Dermocorticoid Reduction in Bullous Pemphigoid (BP)
NCT06148090 — research design, adrenal insufficiency, adrenal cortex hormones, pemphigoid, bullous, physicians, therapeutics, clobetasol		N/ARecruiting2024
Cellular and Molecular Biomarkers in Patients With Lichen Planus
NCT06451744 — skin, cells, epitopes, blood, biopsy, biomarkers, lichens, diagnosis, alphapapillomavirus, lichen planus, mucous membrane, wounds and injuries, membranes, human papillomavirus viruses		N/ARecruiting2023
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
NCT05898308 — injections, skin, antibodies, adrenal cortex hormones, skin diseases, desmogleins, biomarkers, maintenance, rituximab, precision medicine, acantholysis, therapeutics, pemphigus		Phase 4Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS